-
Mashup Score: 5‘IMpassionate conflicts’ in immunotherapy trials for metastatic triple-negative breast cancer - 4 year(s) ago
Triple-negative breast cancer (TNBC) comprises a heterogenous group of breast cancers, with an extremely poor prognosis in patients with metastatic disease. Important advancements have been made in the treatment landscape for TNBC, with most notably the approval of first-line treatment with nanoparticle albumin-bound (nab)-paclitaxel and atezolizumab for patients with programmed death-ligand 1…
Source: Annals of OncologyCategories: Latest Headlines, Oncologists1Tweet
-
Mashup Score: 8Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status - 4 year(s) ago
Assessment of HER2 overexpression using immunohistochemistry (IHC) and/or in situ hybridisation (ISH) for the detection of HER2 amplifications is standard to identify patients for established HER2-directed treatments. Patients with lower HER2 expression levels have recently also become candidates for novel therapies targeting HER2. This study aimed to assess tumour and patient characteristics and…
Source: European Journal of CancerCategories: Latest Headlines, Oncologists1Tweet-
RT @PTarantinoMD: One additional study suggesting no prognostic role for low HER2 expressions in mBC https://t.co/K4mwu6v4id https://t.co/…
-
-
Mashup Score: 10
The authors use single-cell profiling and T cell receptor specificity screening to show how tumour antigen recognition shapes the phenotypes of CD8+ T cells and antitumour immune responses.
Source: NatureCategories: Latest Headlines, Oncologists1Tweet-
RT @DrChoueiri: Stunning paper in @Nature by @DanaFarber Dr Cathy Wu https://t.co/lGYZs75GGm https://t.co/9y7BDAtP50
-
RT @lab_kok: 👇 Our editorial regarding IMpassion130 and 131 landmark studies in Ann Oncol @Annals_Oncology #bcsm https://t.co/eWrghqMY2O